Hemanext has committed its resources to the continuing effort of the transfusion medicine community to save lives and improve patient outcomes. The company is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy.
View Investor Portal for confidential information and updates. Learn about Hemanext ONE technology.
LEXINGTON, Mass., February 02, 2022, PR NEWSWIRE – Hemanext Inc. (“Hemanext” or the “Company”), a...
Hemanext ONE Becomes First Blood Processing and Storage System to Receive Standards-Compliant Seal from AABB
Hemanext Inc. today announced that Hemanext ONE®, its innovative blood processing and storage system, has been recognized by the Association for the Advancement of Blood & Biotherapies (“AABB”), a leading international association in transfusion medicine and biotherapies, for compliance with its industry-recognized quality and safety standards SCoPE Program. The Hemanext ONE® technology is the first system providing both blood processing and storage to receive this designation.
Hemanext Inc., a leading innovator in blood processing and storage technology, announced that it submitted the Hemanext ONE® system for marketing authorization review by the U.S. Food and Drug Administration (FDA) on December 30, 2021.
Hemanext successfully closes series a equity funding round, bringing total raised to more than $100 million
Leading Blood Storage Innovator Expanded Series A Round to Accommodate Interest from Noted Private...
Hemanext Announces that Hypoxic Blood Storage Study has been Recognized as Best Original Research Paper by AABB
Research supports Hemanext’s aim to improve clinical outcomes of transfusion recipients with its...
Curated resources for news, contact information, and newsletter sign-up.